Topics: Bipolar Depression | Bipolar Disorder | Bipolar II | Diagnosis | DSM | Hypomania | Mania | Mixed Features | Mood

Gordon Parker takes on the DSM and offers up a practical approach to diagnosing bipolar disorder. Included is a new self-rated scale that Dr. Parker developed to separate normal good moods from hypomania.

Topics: Alternative treatments | Complimentary Medicine | DASH diet | natural treatments | Nutrition | Therapy during medication appointment

Nutritional psychiatry has come of age with three randomized controlled trials supporting its role in depression. Drew Ramsey, MD, explains how to blend these techniques in with old-school treatments.

Topics: ADHD | Alpha Agonists | Amphetamines | ArModafinil | Atomoxetine | Attention Deficit Hyperactivity Disorder | Bipolar Disorder | Bipolar II | Comorbidity | Guanfacine | methylphenidate | Modafinil | Nuvigil | Pharmacology | Provigil | Psychopharmacology | Psychopharmacology Tips | stimulant | Stimulants

Are stimulants risky in bipolar disorder? And which is safer – methylphenidate or amphetamine? Chris Aiken, MD, lays out a practical approach to the overlap of bipolar disorder and ADHD.

Topics: Aducanumab | Aduhelm | Cognition | Cognitive Decline | Complementary treatments | Dementia | Neurology | News of Note | Novel drug

When the FDA approved aducanumab (Aduhelm) in Alzheimer dementia, the decision came with a heavy dose of controversy. Rehaz Aziz, MD, considers where this novel therapy fits in practice.

Topics: ADHD | Atomoxetine | Attention Deficit Hyperactivity Disorder | Qelbree | Research Update | Viloxazine

This repurposed antidepressant was recently approved in ADHD, but how does it compare with other treatments?

Topics: Geriatric Psychiatry | Hearing loss | Research Update

A simple intervention improves depression in patients with hearing loss.

Topics: Antipsychotics | Dose Response | Dosing | Lurasidone | Schizophrenia

Study suggests we may be underdosing this antipsychotic in schizophrenia.

Topics: Antipsychotics | Lithium | Second Generation Antipsychotics (SGAs) | Side Effects | Sleep | Sleep Disorders | Somnambulism

Sleepwalking is a rare side effect on psychiatric medications, particularly hypnotics and antidepressants. A new analysis explores whether lithium and the antipsychotics should be added to that list.

Topics: Aducanumab | Cognition | Dementia | FDA | Neurology | Novel drug

In the last five years, more psychotropics have gained approval through the FDA’s expedited pathways than the slow and cautious routes we’ve grown used to. These “fast-track” and “breakthrough therapy” approvals allow drugs to enter the market on the basis of more efficient (ie, smaller) clinical trials.

Topics: CME Post-Test

The post-test for this issue is available for one year after the publication date to subscribers. By successfully completing the test you will be awarded a certificate for 2 CME credits.